Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorised blue). Credit: National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH).

Dutch vaccines developer Intravacc has reported positive results from the Phase I clinical trial of its respiratory syncytial virus (RSV) vaccine candidate.

The vaccine candidate was observed to trigger immunogenicity following nasal administration in healthy adults aged 18 to 50. Investigators also reported the candidate to be safe and well-tolerated.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Intravacc’s RSV candidate is a live attenuated vaccine (LAV) made with reverse genetics, without the G (adhesion) protein.

The randomised, placebo-controlled Phase I trial was conducted to assess the safety, tolerability, excretion and immunogenicity of the vaccine.

In preclinical studies, RSVDG led to a reduction in host cell binding and infectivity.

Intranasal immunisation of the RSVDG vaccine in laboratory animals also showed protection against replication of wild-type RSV, without disease aggravation.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

An RSV without the G-protein is expected to be attenuated and induce an effective immune response because of the surface protein F as the major antigen site and residual infectivity.

During the Phase I trial, participants were given one dose of vaccine intranasally compared to a placebo.

The side effects of the vaccine were mild and comparable to the placebo group. After administration, no measurable amounts of vaccine were excreted according to the company.

Measured antibody levels were reported to be comparable before and after immunisation, as well as between vaccine and placebo arms.

Intravacc CEO Dr Jan Groen said: “Although the development of an RSV vaccine is very complex, our live attenuated vaccine provides an important first step in the clinical development of an ultimately effective vaccine.

“We look forward to working with targeted industry partners for the further joint development of this promising vaccine.”

Intravacc is currently seeking a partner for joint clinical development of this vaccine in a large paediatric setting.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact